Department of Pediatrics, Weill Medical College of Cornell University, New York, New York, United States of America.
PLoS One. 2011 Mar 1;6(3):e16874. doi: 10.1371/journal.pone.0016874.
We present a new antiviral strategy and research tool that could be applied to a wide range of enveloped viruses that infect human beings via membrane fusion. We test this strategy on two emerging zoonotic henipaviruses that cause fatal encephalitis in humans, Nipah (NiV) and Hendra (HeV) viruses. In the new approach, artificial cell-like particles (protocells) presenting membrane receptors in a biomimetic manner were developed and found to attract and inactivate henipavirus envelope glycoprotein pseudovirus particles, preventing infection. The protocells do not accumulate virus during the inactivation process. The use of protocells that interact with, but do not accumulate, viruses may provide significant advantages over current antiviral drugs, and this general approach may have wide potential for antiviral development.
我们提出了一种新的抗病毒策略和研究工具，可应用于通过膜融合感染人类的广泛包膜病毒。我们在两种新兴的人畜共患亨尼帕病毒（引起人类致命脑炎的尼帕（NiV）和亨德拉（HeV）病毒）上测试了这种策略。在新方法中，以仿生方式呈现膜受体的人工类细胞颗粒（原细胞）被开发出来，并发现它们可以吸引和失活亨尼帕病毒包膜糖蛋白假病毒颗粒，从而阻止感染。原细胞在失活过程中不会积累病毒。使用与病毒相互作用但不积累病毒的原细胞可能比现有抗病毒药物具有显著优势，这种通用方法可能具有广泛的抗病毒开发潜力。
